Related Experiment Videos
[Interferon-alpha therapy in non-Hodgkin's lymphoma]
1I. Medizinischen Abteilung, des A.ö. Krankenhauses Linz.
Wiener Medizinische Wochenschrift (1946)
|January 1, 1993
Summary
Interferon-alpha (IFN-alpha) shows promise in treating certain blood cancers like hairy-cell leukemia and low-grade non-Hodgkin lymphomas (NHL). Research indicates it may also extend chemotherapy-induced remissions in these hematologic malignancies.
Area of Science:
- Oncology
- Immunology
- Hematology
Context:
- Interferon-alpha (IFN-alpha) possesses antiviral, differentiating, immunomodulatory, and antiproliferative properties.
- Its therapeutic potential has been explored across various malignant diseases.
Purpose:
- To evaluate the efficacy of Interferon-alpha (IFN-alpha) in hematologic malignancies.
- To assess its role in treating specific subtypes of non-Hodgkin lymphomas (NHL) and hairy-cell leukemias.
Summary:
- IFN-alpha is an established treatment for hairy-cell leukemia.
- It demonstrates efficacy in low-grade non-Hodgkin lymphomas (NHL), with average remission rates of 46%, influenced by histologic subtype and tumor burden.
- Remission durations are comparable to conventional therapies, but recent data suggest it may prolong chemotherapy-induced remissions.
Impact:
- IFN-alpha has a significant role in managing specific hematologic cancers.
- Further research may solidify its use in combination therapies to enhance patient outcomes and prolong remission durations.